TY  - JOUR
AU  - Romaguera, Rafael
AU  - Salinas, Pablo
AU  - Gomez-Lara, Josep
AU  - Brugaletta, Salvatore
AU  - Gómez-Menchero, Antonio
AU  - Romero, Miguel A
AU  - García-Blas, Sergio
AU  - Ocaranza, Raymundo
AU  - Bordes, Pascual
AU  - Kockar, Marcelo Jiménez
AU  - Salvatella, Neus
AU  - Jiménez-Díaz, Victor A
AU  - Alameda, Mar
AU  - Trillo, Ramiro
AU  - Lee, Dae Hyun
AU  - Martín, Pedro
AU  - López-Benito, María
AU  - Freites, Alfonso
AU  - Pascual-Tejerina, Virginia
AU  - Hernández-Hernández, Felipe
AU  - Blanco, Bruno García Del
AU  - Mohandes, Mohsen
AU  - Bosa, Francisco
AU  - Pinar, Eduardo
AU  - Roura, Gerard
AU  - Comin-Colet, Josep
AU  - Fernández-Ortiz, Antonio
AU  - Macaya, Carlos
AU  - Rossello, Xavier
AU  - Sabate, Manel
AU  - Pocock, Stuart J
AU  - Gómez-Hospital, Joan A
AU  - SUGAR trial investigators
PY  - 2022
DO  - 10.1093/eurheartj/ehab790
UR  - http://hdl.handle.net/10668/19766
T2  - European heart journal
AB  - Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an...
LA  - en
KW  - Diabetes mellitus
KW  - Drug-eluting stents
KW  - Percutaneous coronary intervention
KW  - Randomized trial
KW  - Coronary Artery Disease
KW  - Diabetes Mellitus
KW  - Drug-Eluting Stents
KW  - Humans
KW  - Percutaneous Coronary Intervention
KW  - Prosthesis Design
KW  - Sirolimus
KW  - Treatment Outcome
TI  - Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.
TY  - research article
VL  - 43
ER  -